I’m with you Nidan; if the upcoming 5 presentations/conferences provide continuing & confirmatory efficacy showing restoration of cellular homeostasis and cognitive stabilization and/or improvement (and on a dose dependent basis), then this investor will frankly be perplexed as to how we could not be then valued at 1-2 billion market cap.
There just seems to be too much positive confluence for a2-73 these days to be ignored by the market, if these upcoming events continue to illustrate.
Just my opinion and 2 cents. Though others will be quick to remind me that this biotech stuff is tricky.
News 
Market Data 
Discover 
